These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 149988)

  • 21. Monoaminergic control of episodic growth hormone secretion in the rat: effects of reserpine, alpha-methyl-p-tyrosine, p-chlorophenylalanine, and haloperidol.
    Edén S; Bolle P; Modigh K
    Endocrinology; 1979 Aug; 105(2):523-9. PubMed ID: 156637
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of catecholamines in the central effects of amphetamine.
    Pfeifer AK; György L; Fodor M
    Acta Med Acad Sci Hung; 1968; 25(3):441-50. PubMed ID: 5720870
    [No Abstract]   [Full Text] [Related]  

  • 23. Comparison of the locomotor stimulant mechanisms of action of d-amphetamine and d-amphetamine plus l-dopa: possible involvement of serotonin.
    Neuburg J; Thut PD
    Biol Psychiatry; 1974 Apr; 8(2):139-50. PubMed ID: 4276374
    [No Abstract]   [Full Text] [Related]  

  • 24. Antagonism of D-amphetamine by alpha-methyl-L-tyrosine: behavioral evidence for the participation of catecholamine stores and synthesis in the amphetamine stimulant response.
    Stolk JM; Rech RH
    Neuropharmacology; 1970 May; 9(3):249-63. PubMed ID: 4393182
    [No Abstract]   [Full Text] [Related]  

  • 25. Involvement of brain monoamines in the stimulant and paradoxical inhibitory effects of methylphenidate.
    Breese GR; Cooper BR; Hollister AS
    Psychopharmacologia; 1975 Oct; 44(1):5-10. PubMed ID: 128026
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of the effectiveness of deserpidine, reserpine, and alpha-methyltyrosine on brain biogenic amines.
    Fulton SC; Healy MD
    Fed Proc; 1976 Dec; 35(14):2558-62. PubMed ID: 11134
    [No Abstract]   [Full Text] [Related]  

  • 27. Biogenic amines and narcotic effects. I. Modification of morphine-induced analgesia and motor activity after alteration of cerebral amine levels.
    Buxbaum DM; Yarbrough GG; Carter ME
    J Pharmacol Exp Ther; 1973 May; 185(2):317-27. PubMed ID: 4267383
    [No Abstract]   [Full Text] [Related]  

  • 28. Effects of lesions and drugs on brain tryptamine.
    Marsden CA; Curzon G
    J Neurochem; 1974 Dec; 23(6):1171-6. PubMed ID: 4281442
    [No Abstract]   [Full Text] [Related]  

  • 29. Effects of d-amphetamine and dopamine synthesis inhibitors on dopamine and acetylcholine neurotransmission in the striatum. I. Release in the absence of vesicular transmitter stores.
    Parker EM; Cubeddu LX
    J Pharmacol Exp Ther; 1986 Apr; 237(1):179-92. PubMed ID: 3007736
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of dietary tyrosine on L-dopa- and amphetamine-induced changes in locomotor activity and neurochemistry in mice.
    Thurmond JB; Freeman GB; Soblosky JS; Ieni JR; Brown JW
    Pharmacol Biochem Behav; 1990 Oct; 37(2):259-66. PubMed ID: 2080188
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of brain monoamines in the fatal hyperthermia induced by pethidine or imipramine in rabbits pretreated with a monoamine oxidase inhibitor.
    Gong SN; Rogers KJ
    Br J Pharmacol; 1973 May; 48(1):12-8. PubMed ID: 4269286
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A comparison of the effects of d-amphetamine and morphine upon the locomotor activity of mice treated with drugs which alter brain catecholamine content.
    Villarreal JE; Guzman M; Smith CB
    J Pharmacol Exp Ther; 1973 Oct; 187(1):1-7. PubMed ID: 4746328
    [No Abstract]   [Full Text] [Related]  

  • 33. Effect of deserpidine and pargyline on the levels of biogenic amines in brain, liver and heart of mice.
    Everett GM; Borcherding J; Morse P
    Res Commun Chem Pathol Pharmacol; 1972 Mar; 3(2):245-8. PubMed ID: 4679851
    [No Abstract]   [Full Text] [Related]  

  • 34. The effect of low doses of d-amphetamine on drug-induced hyperactivity in the mouse.
    Hussey JS; Vincent ND; Davies JA
    Psychopharmacology (Berl); 1983; 81(4):327-31. PubMed ID: 6228947
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of brain norepinephrine in the anorexic effects of dextroamphetamine and monoamine oxidase inhibitors in the rat.
    Holtzman SG; Jewett RE
    Psychopharmacologia; 1971; 22(2):151-61. PubMed ID: 5124188
    [No Abstract]   [Full Text] [Related]  

  • 36. Involvement of brain serotonin in the stimulant action of amphetamine and of cholinolytics.
    Lapin IP; Oxenkrug GF; Azbekyan SG
    Arch Int Pharmacodyn Ther; 1972 Jun; 197(2):350-61. PubMed ID: 4260601
    [No Abstract]   [Full Text] [Related]  

  • 37. Effects of 6-hydroxydopamine treatments on active avoidance responding: evidence for involvement of brain dopamine.
    Cooper BR; Breese GR; Grant LD; Howard JL
    J Pharmacol Exp Ther; 1973 May; 185(2):358-70. PubMed ID: 4703827
    [No Abstract]   [Full Text] [Related]  

  • 38. Role of brain amines in learning associated with "amphetamine-state".
    Roffman M; Lal H
    Psychopharmacologia; 1972; 25(3):195-204. PubMed ID: 4402958
    [No Abstract]   [Full Text] [Related]  

  • 39. Effect of depletion of cerebral monoamines on the concentration of glycogen and on amphetamine-induced glycogenolysis in the brain.
    Hutchins DA; Rogers KJ
    Br J Pharmacol; 1973 May; 48(1):19-29. PubMed ID: 4269287
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Changes in brain norepinephrine associated with sensitization to d-amphetamine.
    Short PH; Shuster L
    Psychopharmacology (Berl); 1976 Jul; 48(1):59-67. PubMed ID: 9657
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.